Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation
about
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaPhosphoinositide 3-kinase: friend and foe in cardiovascular diseaseNo contribution of IP3-R(2) to disease phenotype in models of dilated cardiomyopathy or pressure overload hypertrophy.Protein Kinases as Drug Development Targets for Heart Disease TherapyScreening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.Norepinephrine-Induced Adrenergic Activation Strikingly Increased the Atrial Fibrillation Duration through β1- and α1-Adrenergic Receptor-Mediated Signaling in Mice.Phosphoinositide 3-kinase (PI3K(p110alpha)) directly regulates key components of the Z-disc and cardiac structure.Deletion of PDK1 causes cardiac sodium current reduction in miceProlonged action potential duration in cardiac ablation of PDK1 miceCardiac-specific deletion of the microtubule-binding protein CENP-F causes dilated cardiomyopathyCancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart functionInhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure OverloadLong-term p110α PI3K inactivation exerts a beneficial effect on metabolismPharmacogenetics of Potassium Channel Blockers.Cardiac aging and insulin resistance: could insulin/insulin-like growth factor (IGF) signaling be used as a therapeutic target?An introduction to murine models of atrial fibrillationTherapeutic applications of PI3K inhibitors in cardiovascular diseases.Effect of catheter ablation on progression of paroxysmal atrial fibrillation.Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.Arrhythmic complications of tyrosine kinase inhibitors.Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.Gene Array Analyzer: alternative usage of gene arrays to study alternative splicing eventsThe role of PI3Kα isoform in cardioprotection.Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease.Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment.Impact of Renal Denervation on Atrial Arrhythmogenic Substrate in Ischemic Model of Heart Failure.Rhodiola Inhibits Atrial Arrhythmogenesis in a Heart Failure Model.Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs.Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts.Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic.The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection.Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes.The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice.
P2860
Q26738946-4FED2E80-5D37-4B5D-9A93-B5EF228FD0C1Q26765624-19D25039-C9CC-4926-9993-0CF8B459FF91Q26796228-CFADC05D-34B5-4450-8641-DC26872C3ED8Q33641690-F5534E73-63F5-4B25-9444-36A287C4174CQ33678033-93396F82-0C83-4170-BD91-E0B6568801DFQ33911355-B034AFCD-1F77-4B6F-9071-88AEDD13513CQ34486523-25C1E1A7-C8A9-434E-9920-12B3ACD312A3Q35182995-C10637E9-5152-4162-916F-FF7BAF4C7075Q35188267-3AE8FD06-5CE8-4EED-83A7-F500C25A5F78Q35791798-E19EF49F-6BD3-455E-9767-45641E3BB86CQ36051051-D02F7465-C255-4212-9EB2-373C18235B4AQ36061754-D5DEF82C-7502-4474-98D9-FA53F68C217BQ36378477-03FCA103-2524-4833-B067-FAB48914825AQ36634367-0A24F3BA-F92A-4DCE-A9A9-04B9A10F8CA7Q36771317-4472F142-B42A-49FC-ADD3-C1EC31942DB3Q36970927-987037DB-04F5-4106-82C0-42AF775ACC35Q37442678-1A74A5D7-31EF-4873-A91E-D06A1D67D0DFQ38039083-5FC7C235-D852-4FD4-A1DE-B68CC3E0343EQ38089742-C51B2B04-A84E-476B-BAD6-B67DE686F61DQ38427159-4BCFA62A-8867-4C3E-963E-53D43EB02080Q38815946-C93D0F10-6B20-4F06-A7B8-A975BEEF893EQ38944823-D7212457-B142-4C54-9242-6FEE01B88E73Q38978097-305039AE-0A7C-4873-A006-97FB395E7FF8Q39154824-B133CC1D-20E4-4D29-94CD-1C452746D45BQ39325783-0166601F-D087-45C1-97A0-864641377F90Q39383524-07681B09-129E-44CB-81FA-BC45AE65FC77Q39436207-041105F8-B0D0-4467-AF86-DE20B4B1DB62Q42683501-43A53AE6-6B8A-41E1-AE8E-92D158C7A9F8Q45289568-CFF172A2-4BFC-482D-B237-5F518380DEFDQ47121794-D0BB3193-1EEA-4F80-8ECA-B1C487EB8DCAQ47649543-5B13602A-837E-4733-970A-FA705C939CEBQ48053517-628DA293-CCCD-44EC-A15E-0ABE65BF2035Q48211539-D82FFC6E-8DA1-4E6C-BF59-8340EDA7CA1DQ49917356-7593E38A-482B-41D3-B941-C3EAADE5FC06Q50121608-E4DFBD58-B5C6-4BC8-BFE3-9E867ED83B34Q52644018-5B922AB9-0BC0-4714-8E69-79440F190F22Q54139767-EFDFF3C1-0771-4379-A612-DD97DB10B6E9Q54260332-418759F6-9DC9-4553-AD46-8AC2F61FEB4EQ54481875-98D0DD5D-6DF4-4E20-9C90-C591FBB9C202Q55069411-6E686F7F-8DA7-4970-91EA-BCD78374797F
P2860
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reduced phosphoinositide 3-kin ...... ibility to atrial fibrillation
@en
Reduced phosphoinositide 3-kinase
@nl
type
label
Reduced phosphoinositide 3-kin ...... ibility to atrial fibrillation
@en
Reduced phosphoinositide 3-kinase
@nl
prefLabel
Reduced phosphoinositide 3-kin ...... ibility to atrial fibrillation
@en
Reduced phosphoinositide 3-kinase
@nl
P2093
P2860
P50
P1476
Reduced phosphoinositide 3-kin ...... ibility to atrial fibrillation
@en
P2093
Elizabeth A Woodcock
Helen Kiriazis
Joon Win Tan
Julie R McMullen
Nelly Cemerlang
Robert L Medcalf
Ruby C Y Lin
Seigo Izumo
Silvana Marasco
Tetsuo Shioi
P2860
P304
P356
10.2353/AJPATH.2009.090126
P407
P50
P577
2009-08-13T00:00:00Z